Venture Life Group (VLG) Competitors

Venture Life Group logo
GBX 66.50 -2.00 (-2.92%)
As of 11/20/2026 11:59 AM Eastern

VLG vs. BXP, ANCR, BVXP, AGY, and ORPH

Should you buy Venture Life Group stock or one of its competitors? Venture Life Group's main competitors and comparable companies include Beximco Pharmaceuticals (BXP), Animalcare Group (ANCR), Bioventix (BVXP), Allergy Therapeutics (AGY), and Open Orphan (ORPH). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Venture Life Group compare to Beximco Pharmaceuticals?

Beximco Pharmaceuticals (LON:BXP) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, earnings, risk, profitability, media sentiment, valuation and dividends.

Beximco Pharmaceuticals has higher revenue and earnings than Venture Life Group. Beximco Pharmaceuticals is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Beximco Pharmaceuticals£56.27B0.00£970.84B£1.94 thousand0.03
Venture Life Group£35.17M2.25£747.21K£4.3715.22

Venture Life Group has a net margin of 17.42% compared to Beximco Pharmaceuticals' net margin of 16.93%. Beximco Pharmaceuticals' return on equity of 15.99% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Beximco Pharmaceuticals16.93% 15.99% 6.97%
Venture Life Group 17.42%7.82%1.56%

Beximco Pharmaceuticals has a beta of 0.248, meaning that its stock price is 75% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.234, meaning that its stock price is 77% less volatile than the broader market.

0.3% of Beximco Pharmaceuticals shares are owned by institutional investors. Comparatively, 20.7% of Venture Life Group shares are owned by institutional investors. 4.2% of Beximco Pharmaceuticals shares are owned by company insiders. Comparatively, 7.7% of Venture Life Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Beximco Pharmaceuticals' average media sentiment score of 0.00 equaled Venture Life Group'saverage media sentiment score.

Company Overall Sentiment
Beximco Pharmaceuticals Neutral
Venture Life Group Neutral

Summary

Beximco Pharmaceuticals beats Venture Life Group on 6 of the 11 factors compared between the two stocks.

How does Venture Life Group compare to Animalcare Group?

Venture Life Group (LON:VLG) and Animalcare Group (LON:ANCR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, valuation, media sentiment, risk, earnings and profitability.

Venture Life Group has a net margin of 17.42% compared to Animalcare Group's net margin of 5.70%. Venture Life Group's return on equity of 7.82% beat Animalcare Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Animalcare Group 5.70%4.46%2.97%

In the previous week, Venture Life Group's average media sentiment score of 0.00 equaled Animalcare Group'saverage media sentiment score.

Company Overall Sentiment
Venture Life Group Neutral
Animalcare Group Neutral

20.7% of Venture Life Group shares are owned by institutional investors. Comparatively, 14.3% of Animalcare Group shares are owned by institutional investors. 7.7% of Venture Life Group shares are owned by insiders. Comparatively, 30.1% of Animalcare Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Animalcare Group has higher revenue and earnings than Venture Life Group. Venture Life Group is trading at a lower price-to-earnings ratio than Animalcare Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.25£747.21K£4.3715.22
Animalcare Group£89.11M2.60£36.55M£7.3045.89

Venture Life Group has a beta of 0.234, suggesting that its stock price is 77% less volatile than the broader market. Comparatively, Animalcare Group has a beta of 0.67, suggesting that its stock price is 33% less volatile than the broader market.

Summary

Animalcare Group beats Venture Life Group on 8 of the 11 factors compared between the two stocks.

How does Venture Life Group compare to Bioventix?

Bioventix (LON:BVXP) and Venture Life Group (LON:VLG) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, earnings, institutional ownership, dividends, valuation and risk.

Bioventix has a beta of 0.541, indicating that its share price is 46% less volatile than the broader market. Comparatively, Venture Life Group has a beta of 0.234, indicating that its share price is 77% less volatile than the broader market.

Bioventix has higher earnings, but lower revenue than Venture Life Group. Bioventix is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Bioventix£12.97M7.64£8.12M£143.6213.21
Venture Life Group£35.17M2.25£747.21K£4.3715.22

20.6% of Bioventix shares are owned by institutional investors. Comparatively, 20.7% of Venture Life Group shares are owned by institutional investors. 6.2% of Bioventix shares are owned by company insiders. Comparatively, 7.7% of Venture Life Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Bioventix has a net margin of 58.70% compared to Venture Life Group's net margin of 17.42%. Bioventix's return on equity of 67.81% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Bioventix58.70% 67.81% 54.07%
Venture Life Group 17.42%7.82%1.56%

In the previous week, Bioventix's average media sentiment score of 0.00 equaled Venture Life Group'saverage media sentiment score.

Company Overall Sentiment
Bioventix Neutral
Venture Life Group Neutral

Summary

Bioventix beats Venture Life Group on 7 of the 11 factors compared between the two stocks.

How does Venture Life Group compare to Allergy Therapeutics?

Venture Life Group (LON:VLG) and Allergy Therapeutics (LON:AGY) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability, media sentiment and institutional ownership.

Venture Life Group has a net margin of 17.42% compared to Allergy Therapeutics' net margin of -86.04%. Allergy Therapeutics' return on equity of 1,684.19% beat Venture Life Group's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Allergy Therapeutics -86.04%1,684.19%-34.76%

20.7% of Venture Life Group shares are held by institutional investors. Comparatively, 0.0% of Allergy Therapeutics shares are held by institutional investors. 7.7% of Venture Life Group shares are held by insiders. Comparatively, 3.6% of Allergy Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Allergy Therapeutics had 4 more articles in the media than Venture Life Group. MarketBeat recorded 4 mentions for Allergy Therapeutics and 0 mentions for Venture Life Group. Allergy Therapeutics' average media sentiment score of 0.02 beat Venture Life Group's score of 0.00 indicating that Allergy Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Venture Life Group Neutral
Allergy Therapeutics Neutral

Venture Life Group has a beta of 0.234, indicating that its stock price is 77% less volatile than the broader market. Comparatively, Allergy Therapeutics has a beta of 0.835, indicating that its stock price is 17% less volatile than the broader market.

Venture Life Group has higher earnings, but lower revenue than Allergy Therapeutics. Allergy Therapeutics is trading at a lower price-to-earnings ratio than Venture Life Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.25£747.21K£4.3715.22
Allergy Therapeutics£59.87M1.19-£52.59M-£0.97N/A

Summary

Venture Life Group beats Allergy Therapeutics on 8 of the 13 factors compared between the two stocks.

How does Venture Life Group compare to Open Orphan?

Venture Life Group (LON:VLG) and Open Orphan (LON:ORPH) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

Venture Life Group has a net margin of 17.42% compared to Open Orphan's net margin of 0.00%. Venture Life Group's return on equity of 7.82% beat Open Orphan's return on equity.

Company Net Margins Return on Equity Return on Assets
Venture Life Group17.42% 7.82% 1.56%
Open Orphan N/A N/A N/A

20.7% of Venture Life Group shares are owned by institutional investors. 7.7% of Venture Life Group shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Venture Life Group's average media sentiment score of 0.00 equaled Open Orphan'saverage media sentiment score.

Company Overall Sentiment
Venture Life Group Neutral
Open Orphan Neutral

Venture Life Group has higher revenue and earnings than Open Orphan.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Venture Life Group£35.17M2.25£747.21K£4.3715.22
Open Orphan£34.71M0.00N/AN/AN/A

Summary

Venture Life Group beats Open Orphan on 7 of the 7 factors compared between the two stocks.

Get Venture Life Group News Delivered to You Automatically

Sign up to receive the latest news and ratings for VLG and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VLG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VLG vs. The Competition

MetricVenture Life GroupPharmaceuticals IndustryHealthcare SectorLON Exchange
Market Cap£79.05M£13.62B£7.78B£2.67B
Dividend Yield0.09%2.58%2.47%5.11%
P/E Ratio15.2227.5233.2222.78
Price / Sales2.256.788.104.91
Price / Cash6.4015.6321.0120.23
Price / Book1.135.164.262.40
Net Income£747.21K£2.86B£3.50B£5.88B
1 Month Performance-1.34%-9.80%-10.48%-4.75%
1 Year Performance12.73%-8.93%-4.61%5.15%

Venture Life Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VLG
Venture Life Group
N/AGBX 66.50
-2.9%
N/A+13.3%£79.05M£35.17M15.22165
BXP
Beximco Pharmaceuticals
N/AGBX 63
+5.0%
N/A+39.3%£281.05M£53.93B0.035,500
ANCR
Animalcare Group
N/AGBX 335
flat
N/AN/A£231.30M£89.11M45.89220
BVXP
Bioventix
N/AGBX 1,935.56
-0.7%
N/A-9.3%£101.13M£12.97M13.4812
AGY
Allergy Therapeutics
N/AGBX 1.25
-3.5%
N/A-87.2%£79.16M£57.29MN/A612

Related Companies and Tools


This page (LON:VLG) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners